Zentiva Italia SRL Pharmaceutical Import Profile — Italy (DGFT 2022–2026)

Name: Zentiva Italia SRL Pharmaceutical Import Records from India — 2 Products, $7.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Zentiva Italia SRL — Pharmaceutical Importer Profile (2026) | 2 Products, $7.0M Trade | TransData Nexus

Zentiva Italia SRL

Pharmaceutical Importer · Italy · Cardiovascular Focus · $7.0M Total Trade · DGFT Verified

Zentiva Italia SRL is a pharmaceutical importer based in Italy with a total trade value of $7.0M across 2 products in 1 therapeutic categories. Based on 234 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Zentiva Italia SRL sources from 1 verified Indian supplier, with Zentiva Private Limited accounting for 100.0% of imports.

Zentiva Italia SRL — Import Portfolio & Supplier Network

Zentiva Italia SRL import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Zentiva Italia SRL?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Zentiva Private Limited	$9.0M	333	100.0%

Zentiva Italia SRL sources from 1 verified Indian supplier across 120 distinct formulations. The sourcing is highly concentrated — Zentiva Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Zentiva Italia SRL Import?

Formulation	Value	Ships
Pharmaceutical products - ramipril ztv	$624.2K	21
Pharmaceutical article / ods / product / item - clopidogrel	$617.4K	13
Pharmaceutical products - ramipril ztv	$605.5K	20
Pharmaceutical products - clopidogrel	$437.5K	9
Pharmaceutical products - zuglimet 1g	$405.1K	16
Pharmaceutical products - clopidogrel	$384.2K	8
Pharmaceutical products - zuglimet 500MG	$353.0K	12
Pharmaceutical products - zuglimet	$256.7K	10
Pharmaceutical products - ramipril hct	$214.7K	11
Pharmaceutical products clopidogrel	$200.0K	4
Pharmaceutical products - clopidogrel ztv 75MG tabco bl2x14 m36	$193.9K	5
Pharmaceutical products - ramipril ztv	$183.6K	5
Pharmaceutical article / ods / product / item - ramipril ztv	$183.4K	6
Pharmaceutical products - zuglimet	$159.1K	6
Pharmaceutical products - clopidogrel ztv 75MG tabco bl2x14 m36 it (261839 pcs)	$127.1K	3

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ramipril	Cardiovascular	$3.8M	169	4.3%	6
2	Clopidogrel	Cardiovascular	$3.2M	65	1.3%	15

Zentiva Italia SRL imports 2 pharmaceutical products across 1 categories into Italy totaling $7.0M.

Zentiva Italia SRL — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Zentiva Italia S.r.l., established in 1995, is a pharmaceutical importer and distributor headquartered in Milan, Italy. As a subsidiary of the pan-European pharmaceutical company Zentiva, based in Prague, Czech Republic, it plays a pivotal role in delivering high-quality, affordable medicines to the Italian market. Zentiva Italia's portfolio encompasses generic drugs, specialty pharmaceuticals, and over-the-counter (OTC) products, focusing on therapeutic areas such as cardiology, oncology, respiratory conditions, and central nervous system disorders. (zentiva.it)

The company operates under the legal framework of a Società a Responsabilità Limitata (S.r.l.), a limited liability company, with a registered capital of €1,000,000 as of 2026. In 2024, Zentiva Italia reported a turnover of €98,494,313, reflecting its significant presence in the pharmaceutical distribution sector. (ufficiocamerale.it) With a dedicated team of approximately 109 employees, the company is committed to ensuring the availability of essential medicines across Italy. (ufficiocamerale.it)

2Distribution Network

Zentiva Italia S.r.l. maintains a robust distribution network to ensure the efficient delivery of pharmaceutical products throughout Italy. While specific warehouse locations are not publicly disclosed, the company's strategic positioning in Milan, a central hub for logistics, facilitates effective nationwide distribution. The company leverages advanced logistics capabilities to manage a diverse portfolio of products, ensuring timely and reliable supply to various healthcare providers, including hospitals, pharmacies, and clinics. This infrastructure supports Zentiva Italia's mission to provide accessible healthcare solutions across the country.

3Industry Role

In Italy's pharmaceutical supply chain, Zentiva Italia S.r.l. functions primarily as a pharmaceutical importer and distributor. The company sources a wide range of pharmaceutical products from international manufacturers, including active pharmaceutical ingredients (APIs) and finished dosage forms, to meet the diverse needs of the Italian market. By importing and distributing these products, Zentiva Italia ensures the availability of essential medicines, contributing to the overall health and well-being of the Italian population.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Zentiva Italia SRL

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Zentiva Italia S.r.l. demonstrates a high degree of sourcing concentration, with a total import value from India amounting to $7.0 million USD across 234 shipments. The company's portfolio is exclusively focused on cardiovascular products, specifically Ramipril and Clopidogrel, imported from a single supplier, Zentiva Private Limited. This single-source dependency indicates a strategic choice to maintain a streamlined supply chain and ensure consistent product quality. However, it also presents potential risks, such as supply disruptions or changes in supplier terms, which could impact Zentiva Italia's ability to meet market demand.

The shipment data reveals a stable and consistent relationship with Zentiva Private Limited, suggesting a reliable supply chain. Nonetheless, the lack of diversification in sourcing could expose Zentiva Italia to vulnerabilities, especially in the event of geopolitical issues, regulatory changes, or operational challenges faced by the supplier. To mitigate these risks, it would be prudent for Zentiva Italia to consider diversifying its supplier base and exploring alternative sources for its key products.

2Supply Chain Resilience

Zentiva Italia S.r.l.'s supply chain resilience is closely tied to its exclusive reliance on Zentiva Private Limited for the import of Ramipril and Clopidogrel. This singular sourcing strategy may limit the company's ability to adapt to supply chain disruptions or fluctuations in demand. The absence of backup suppliers for these critical products suggests a potential vulnerability in maintaining uninterrupted supply to the Italian market.

Importing Pharmaceuticals into Italy — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Italy

1Regulatory Authority & Framework

In Italy, the primary regulatory authority overseeing the pharmaceutical sector is the Italian Medicines Agency (AIFA). AIFA is responsible for the evaluation, authorization, and monitoring of medicinal products to ensure their safety, efficacy, and quality. The agency operates under the framework of both national and European Union regulations, aligning with directives and regulations set forth by the European Medicines Agency (EMA). This dual framework ensures that Italy's pharmaceutical market adheres to stringent standards, facilitating the availability of safe and effective medicines to the public. (aifa.gov.it)

The marketing authorization pathway for medicinal products in Italy involves a comprehensive evaluation process. Applicants must submit a dossier containing detailed information on the product's chemical-pharmaceutical, preclinical, and clinical aspects, structured according to the Common Technical Document (CTD) format. This dossier undergoes a scientific assessment by AIFA to verify compliance with quality, safety, and efficacy requirements. Once granted, the marketing authorization is valid for five years and is renewable, ensuring continuous oversight of medicinal products in the Italian market. (aifa.gov.it)

2Import Licensing & GMP

Import licensing requirements in Italy are governed by AIFA and the Ministry of Health. Pharmaceutical companies seeking to import medicinal products must obtain the necessary authorizations, which include demonstrating compliance with Good Manufacturing Practices (GMP). GMP certification ensures that manufacturing processes meet the required standards for product quality and safety. Recognized certifications include EU GMP, WHO GMP, and PIC/S standards. Additionally, companies must hold wholesale distribution authorizations to legally distribute medicinal products within Italy. (aifa.gov.it)

Zentiva Italia SRL — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Zentiva Italia S.r.l.'s focus on cardiovascular products, specifically Ramipril and Clopidogrel, aligns with the significant demand for treatments addressing cardiovascular diseases in Italy. The decision to import these products from India reflects a strategic approach to sourcing high-quality generics that offer cost-effective solutions to the Italian healthcare system. By concentrating on these therapeutic areas, Zentiva Italia aims to meet the needs of a substantial patient population, contributing to improved health outcomes and enhanced quality of life.

2Sourcing Profile

Zentiva Italia's sourcing strategy emphasizes the procurement of generic drugs, particularly focusing on formulations that address prevalent health conditions such as cardiovascular diseases. The company's reliance on a single supplier, Zentiva Private Limited, for these products indicates a preference for streamlined operations and established partnerships. This approach suggests a commitment to maintaining consistent product quality and supply reliability. However, the concentration on a limited number of formulations may restrict the company's ability to diversify its product offerings and adapt to evolving market demands.

3Market Positioning

Frequently Asked Questions — Zentiva Italia SRL

What products does Zentiva Italia SRL import from India?

Zentiva Italia SRL imports 2 pharmaceutical products across 1 categories. Top imports: Ramipril ($3.8M), Clopidogrel ($3.2M).

Who supplies pharmaceuticals to Zentiva Italia SRL from India?

Zentiva Italia SRL sources from 1 verified Indian suppliers. The primary supplier is Zentiva Private Limited (100.0% of imports, $9.0M).

What is Zentiva Italia SRL's total pharmaceutical import value?

Zentiva Italia SRL's total pharmaceutical import value from India is $7.0M, based on 234 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Zentiva Italia SRL focus on?

Zentiva Italia SRL imports across 1 categories. The largest: Cardiovascular (100.0%).

Get Full Zentiva Italia SRL Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.